Physician profile
Djwan Scott
NPI 1821336652
$4,279.42
in general payments reported to CMS, 2019-2025
25 companies · $1,339 in 2025
The $1,339 reported for 2025 was more than what 89% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $443 · 2022: $655 · 2023: $1,099 · 2024: $743 · 2025: $1,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,741 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,741.17 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $440.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $651.28 | 2021-2023 | Xarelto |
| Corcept Therapeutics | $440.00 | 2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $350.05 | 2023-2025 | Airsupra, Breztri |
| Abbvie INC. | $315.50 | 2024-2025 | |
| Gilead Sciences, INC. | $241.86 | 2022-2023 | Descovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.15 | 2023-2024 | Jardiance |
| Neurocrine Biosciences, INC. | $209.00 | 2022-2023 | Ingrezza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $198.02 | 2025 | Rexulti |
| Alnylam Pharmaceuticals INC. | $145.73 | 2025 | Amvuttra |
| Madrigal Pharmaceuticals | $131.19 | 2024 | Rezdiffra |
| Cequr Corporation | $130.88 | 2023 | Cequr Simplicity |
| Phathom Pharmaceuticals, INC. | $124.99 | 2024 | Voquezna |
| Mylan Specialty L.P. | $122.70 | 2023 | Yupelri |
| Lilly USA, LLC | $119.71 | 2023 | Mounjaro |
| Glaxosmithkline, LLC. | $119.69 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $104.00 | 2023 | Jynarque |
| Acadia Pharmaceuticals INC | $100.67 | 2025 | Nuplazid |
| Biohaven Pharmaceuticals, INC. | $100.59 | 2021 | |
| Esperion Therapeutics, INC. | $98.43 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $97.66 | 2025 | Cobenfy |
| Redhill Biopharma INC. | $84.04 | 2021 | |
| Merck Sharp & Dohme LLC | $68.58 | 2023 | Verquvo |
| Takeda Pharmaceuticals U.S.A., INC. | $43.75 | 2023 | |
| Scpharmaceuticals INC. | $35.35 | 2025 | |
| Avanir Pharmaceuticals, INC. | $34.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Djwan Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.